Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: The impact of varying the discount rate for health

Abstract To estimate the cost-effectiveness of a potential Helicobacter pylori (HP) vaccine for the Dutch situation, we developed a Markov model. Several HP prevalence scenarios were assessed. Additionally, we assessed the impact of the discount rate for health on the outcomes, as this influence can...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2009-02, Vol.27 (6), p.846-852
Main Authors: de Vries, Robin, Klok, Rogier M, Brouwers, Jacobus R.B.J, Postma, Maarten J
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Allergy and Immunology
Animals
Applied microbiology
Bacterial Vaccines - economics
Bacterial Vaccines - immunology
Bacteriology
Biological and medical sciences
Child
Child, Preschool
Cost-Benefit Analysis
Cost-effectiveness
Discount rate
Female
Fundamental and applied biological sciences. Psychology
Helicobacter Infections - economics
Helicobacter Infections - epidemiology
Helicobacter Infections - prevention & control
Helicobacter pylori
Helicobacter pylori - immunology
Humans
Infant
Infant, Newborn
Male
Markov Chains
Microbiology
Middle Aged
Miscellaneous
Netherlands - epidemiology
Prevalence
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract To estimate the cost-effectiveness of a potential Helicobacter pylori (HP) vaccine for the Dutch situation, we developed a Markov model. Several HP prevalence scenarios were assessed. Additionally, we assessed the impact of the discount rate for health on the outcomes, as this influence can be profound for vaccines. When applying the current discount rate of 1.5% for health, the expected cost-effectiveness of HP vaccination is estimated below the informal Dutch threshold of €20,000/LYG when the HP prevalence is assumed ≥20% in the Dutch population. In conclusion, we showed that HP vaccination could possibly be a cost-effective intervention. However, this depends to a large extend on the prevalence of HP in the population. Furthermore, we showed the large impact of the discount rate for health on the cost-effectiveness of a HP vaccination program, illustrative for other vaccination programs.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2008.11.081